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Abstract
Hereditary angioedema is characterized by sudden episodes of nonpitting edema that cause discomfort and pain.
Typically the extremities, genitalia, trunk, gastrointestinal tract, face, and larynx are affected by attacks of swelling.
Laryngeal swelling carries significant risk for asphyxiation. The disease results from mutations in the C1 esterase
inhibitor gene that cause C1 esterase inhibitor deficiency. Attacks of hereditary angioedema result from contact,
complement, and fibrinolytic plasma cascade activation, where C1 esterase inhibitor irreversibly binds substrates.
Patients with hereditary angioedema cannot replenish C1 esterase inhibitor levels on pace with its binding. When
C1 esterase inhibitor is depleted in these patients, vasoactive plasma cascade products cause swelling attacks.
Trauma is a known trigger for hereditary angioedema attacks, and patients have been denied surgical procedures
because of this risk. However, uncomplicated surgeries have been reported. Appropriate prophylaxis can reduce
peri-operative morbidity in these patients, despite proteolytic cascade and complement activation during surgical
trauma. We report a case of successful short-term prophylaxis with C1 esterase inhibitor in a 51-year-old man with
hereditary angioedema who underwent redo mitral valve reconstructive surgery.
Background
Attacks of hereditary angioedema (HAE) are character-
ized by sudden episodes of brawny, nonpitting edema,
causing discomfort and pain [1]. Areas of the body typi-
cally affected include the extremities, genitalia, trunk,
gastrointestinal tract, face, and larynx. Untreated
patients with HAE are at risk for deadly attacks of laryn-
geal swelling, where up to 30% may asphyxiate [2].
HAE is an inherited autosomal dominant disorder
resulting from any number of mutations in the C1 ester-
ase inhibitor (C1 INH) gene that cause C1 INH defi-
ciency [2]. Approximately 85% of cases are type 1 HAE,
which is characterized by reduced levels of circulating
C1 INH [3,4]. The remaining 15% of cases are type 2
HAE, which is characterized by dysfunctional circulating
C1 INH [3,4]. A child will have a 50% chance of inherit-
ing HAE if one parent has the disease; however, 25% of
cases arise from de novo mutations [3]. Inherited
angioedema with normal C1 inhibitor levels has been
described and is thought to be a separate disease result-
ing from a factor XII missense mutation that leads to
bradykinin overproduction [5,6].
Histamine mediated allergic inflammation is not
involved in HAE [7]. Instead, HAE attacks result from
contact, complement, and fibrinolytic plasma cascade
activation, where C1 INH is a suicide inhibitor [2]. Peo-
ple with HAE have defective C1 INH synthesis with
typical C1 INH levels that are 5%-30% of normal.
2 Bra-
dykinin is generated in large quantities via the contact
pathway once C1 INH is depleted (Figure 1) [2]. Excess
bradykinin production leads to acute HAE attacks as a
result of increased vasodilatation, vascular permeability,
and contraction of nonvascular smooth muscle [3].
HAE affects 1:50,000 people [8]. Fifty percent of
patients will develop symptoms by age 10, although
attacks have been reported in children as young as
2 years old [9]. Symptom frequency and severity may be
extremely variable, even within families [4]. There may
be no obvious trigger for attacks and no correlation
between attack severity and subtype of disease. However,
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women may be responsible for many attacks [10].
Despite the inherent risks of performing surgery on
patients with HAE, the cardiovascular surgery literature
provides examples of uncomplicated surgery in patients
who were methodically prophylaxed with different
agents [11,12]. Appropriate choice of a prophylactic
agent and its judicious use can help surgeons reduce
peri-operative morbidity to patients, despite multiple
sources of proteolytic cascade and complement activa-
tion known to occur with surgical trauma, and more
specifically, with cardiac pump bypass surgeries [13,14].
Previous agents used for prophylactic treatment of
HAE patients undergoing surgery include fresh frozen
plasma, high-dose attenuated androgens, and anti-fibri-
nolytic agents. No agent is currently approved for short-
term procedural prophylaxis. However, newer agents are
approved for long-term prophylaxis (C1 esterase inhibi-
tor [CINRYZE™]) and acute attacks (C1 esterase inhibi-
tor [Berinert P®] and kallikrein inhibitor, ecallantide
[KALBITOR®]). Here we report a case of successful
short-term prophylaxis using C1 INH in a 51-year-old
man with HAE undergoing redo mitral valve reconstruc-
tive surgery.
Case presentation
A 51-year-old man with type2H A E ,ah i s t o r yo fa c u t e
respiratory failure, chronic airway obstruction, adhesive
pericarditis, congestive heart failure, chronic pulmonary
heart disease, and previous mitral valve annuplasty was
scheduled for redo surgery six months after the initial
surgical procedure due to severe mitral valve regurgita-
tion. During the initial surgical procedure, the patient
was successfully prophylaxed with C1 INH and his peri-
operative course was uneventful. Details of the initial
surgery were previously published in abstract form [12].
The patient reported onset of HAE symptoms begin-
ning at age 12. Previous attacks consisted of abdominal,
facial, extremity, and painful genital swelling. He
reported two previous episodes of severe laryngeal
Figure 1 C1 INH action in plasma cascades. Depletion of C1 INH due to plasma cascade activation allows bradykinin overproduction in
patients with hereditary angioedema. Bradykinin mediates acute swelling in these patients. Reproduced with permission from Weis [15].
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trolled on long-term prophylaxis with the attenuated
androgen, danazol 400 mg daily, under the care of an
allergist. However, even while on this medication, he
reported breakthrough swelling including laryngeal
edema. Historically, his C1 INH levels were normal, but
the C1 INH was dysfunctional, and he had a persistently
low C4 level - typical findings in type 2 HAE.
Two months after the initial mitral valve reconstruc-
tion and annuloplasty surgery, the patient presented to
the emergency department in heart failure due to peri-
cardial effusion. The patient’s surgeon and allergist were
consulted prior to any procedure. As a result, the
patient was prophylaxed with C1 INH 1000 units prior
to pericardiocentesis, where one liter of pericardial fluid
was removed. A transesophageal echocardiogram
showed moderated-to-severe mitral valve regurgitation
secondary to failure of previous repair. The procedure
was tolerated without swelling.
The patient was scheduled for redo mitral valve repair
six months later. Laboratory studies prior to surgery
preparations were unremarkable except for chronic ane-
mia. Cardiac catheterization was performed 48 hours
prior to repeat mitral valve reconstruction. C1 INH
1000 units was administered six hours before cardiac
catheterization. Since the patient was on danazol 400
mg daily, his functional C1 INH levels were within the
normal range, but his C4 level remained low. C1 INH
1000 units was again administered intravenously twelve
hours before repeat mitral valve reconstruction. During
the redo surgery, the patient underwent sternotomy
with lysis of extensive mediastinal adhesions, redo mitral
valve repair with resection of chordae tendineae, and
closure of dehisced prior leaflet closure; removal of
annuloplasty band and insertion of 32 CardioMedics
annuloplasty ring; and intraoperative 2-D esophageal
echocardiogram for aortic ultrasound.
The surgery was uncomplicated without excessive
blood loss. The patient experienced no postoperative
complications associated with the surgery or HAE. He
was extubated, the Swan-Ganz was discontinued, and
danazol 400 mg daily prophylaxis was resumed on post-
operative day one. Chest tubes were removed on post-
operative day two, and the patient was transferred to
the regular nursing floor. He was discharged on post-
operative day 4 and instructed to follow-up with the
allergist caring for his HAE as an outpatient.
Conclusions
Three medications are available for acute treatment of
HAE: Berinert-P® (plasma-derived C1 esterase inhibitor,
approved in the US and Europe), KALBITOR® (ecallan-
tide, a kallikrein inhibitor, approved only in the US cur-
rently), and Firazyr® (icatibant, bradykinin b2-receptor
inhibitor, approved only in Europe currently). Two med-
ications are available for long-term prophylaxis: CIN-
RYZE™ (C1 esterase inhibitor [human], approved in the
US) and the attenuated androgen, danazol (approved in
the US and Europe). The newer medications target the
underlying pathology of HAE and have less potential for
long-term side effects than androgens. No medication is
currently approved for procedural prophylaxis. However,
consensus guidelines recommend the use of C1 INH
(Table 1) and there are now many case reports of using
C1 INH pre-operatively in Europe and the US [8,12].
This case demonstrates that major surgery can be per-
formed on HAE patients if care is closely coordinated.
One week after surgery, this patient’s long-term danazol
prophylaxis dosage was reduced to 200 mg once daily.
With close management, this patient now experiences
only a few breakthrough symptoms during normal activ-
ity, and he has needed procedural prophylaxis with C1
INH for a dental procedure only once since his mitral
valve surgery. This case also demonstrates that typical
long-term prophylactic doses of C1 INH may be suffi-
cient for prophylaxis prior to major surgery. Prior to his
initial mitral valve replacement, the patient received
2000 units of C1 INH. However, after consulting an
HAE expert, the doses for subsequent procedures were
reduced to 1000 units with comparable results.
Procedural prophylaxis protocols should include a
thorough patient history, coordinated efforts among
medical specialties, family education, and use of an
appropriate prophylactic medication. The successful use
of a procedural prophylaxis protocol in this case will
hopefully encourage the use of appropriate prophylaxis
in patients with HAE who may be otherwise denied
surgery.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
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Table 1 Consensus guideline C1 INH dosages for
procedural prophylaxis
Patient weight C1 INH dose
≤50 kg 500 units
>50 kg to ≤100 kg 1000 units
>100 kg 1500 units
Administer 1 hour before procedure. Have additional doses available if
needed during and after surgery. C1 INH = C1 esterase inhibitor.
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